Drug-loaded system and drug targeting folr2-positive macrophages and preparation method thereof
By modifying the surface of macrophage microvesicles with anti-Folr2 monoclonal antibodies, a drug delivery system targeting Folr2-positive macrophages was constructed, which solved the problem of the lack of kidney tissue specificity of existing drugs and achieved precise treatment of kidney inflammation and fibrosis.
Patent Information
- Application Number
- CN202611295866.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-25
- Publication Date
- 2026-11-10
AI Technical Summary
Existing drugs for treating kidney inflammation and fibrosis lack specificity for kidney tissue and target cells, resulting in significant systemic toxicity and difficulty in penetrating dense renal interstitial fibrosis tissue, leading to low bioavailability.
By preparing anti-Folr2 monoclonal antibodies and stably modifying them on the surface of macrophage microvesicles, a drug delivery system targeting Folr2-positive macrophages was constructed, and targeted drug delivery was achieved by utilizing Folr2 receptor-mediated endocytosis.
It achieves precise targeting of Folr2-positive macrophages, effectively clears pathogenic cells in kidney tissue, inhibits renal inflammatory infiltration and fibrosis, and is suitable for targeted therapy of acute and chronic kidney disease.
Smart Images

Figure CN123059166A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedicine, specifically relating to an anti-Folr2 antibody and an antibody-drug conjugate targeting Folr2-positive macrophages, as well as their preparation methods and applications. Background Technology
[0002] Folic acid receptor 2 (Folr2, folate receptor β) is an important subtype of the folate receptor family, specifically expressed on the surface of myeloid immune cells. It exhibits significant tissue-specific expression differences compared to folate receptor 1 (Folr1, folate receptor α), which is highly expressed in tumor epithelial cells and normal renal tubular epithelial cells, with no cross-expression characteristics. In pathological models of kidney injury, Folr2-positive macrophages are a core cell subset mediating sustained activation of renal inflammation and promoting fibrosis. These cells can interact with inflammatory fibroblasts to construct a pro-fibrotic microenvironment, inducing massive abnormal deposition of extracellular matrix (ECM), and continuously driving renal function impairment and fibrosis progression. Therefore, specifically targeting, regulating, or reprogramming Folr2-positive macrophages is a key breakthrough in curbing the progression of kidney injury and blocking the development of renal fibrosis.
[0003] Currently, there are many technical shortcomings in clinical treatments for kidney inflammation and fibrosis: Traditional chemotherapy drugs, although possessing potent cell-killing activity, lack specificity for kidney tissue and target cells, easily damaging normal renal tubular epithelial cells, cardiomyocytes, and normal immune cells, resulting in significant systemic toxic side effects; Traditional synthetic liposome nanocarriers, while capable of drug loading, suffer from poor thermodynamic stability, leading to phospholipid oxidation and hydrolysis, drug leakage, and the generation of anti-PEG antibodies that can cause allergies. Furthermore, they are difficult to penetrate dense renal interstitial fibrosis tissue, resulting in extremely poor drug accumulation efficiency and lesion penetration, and low bioavailability.
[0004] Extracellular microvesicles (MPS), as natural bionanocarriers, possess excellent biocompatibility, low immunogenicity, and the ability to penetrate multiple biological barriers. Macrophage-derived microvesicles can retain the inflammatory chemokine receptors and integrin proteins of their parent cells, exhibiting natural targeted enrichment properties in damaged tissues. Currently, there are no reports on the use of macrophage microvesicle carriers and specific Folr2 antibody-modified precision drug delivery systems for the treatment of kidney injury. Therefore, developing Folr2-targeted ADCs based on homologous antibodies, forming two complementary therapeutic strategies with antibody-modified microvesicles, has significant translational value. Summary of the Invention
[0005] This invention prepares an anti-Folr2 monoclonal antibody and stably modifies it onto the surface of macrophage microvesicles using phospholipid cross-linking technology, constructing an antibody-modified biomimetic drug delivery system. This system combines the biological barrier penetration capability of microvesicles, the natural accumulation capacity of macrophages in damaged tissues, and the precise target cell recognition capability of Folr2 antibodies. It achieves targeted drug delivery through Folr2 receptor-mediated endocytosis, precisely regulating the renal pathological microenvironment.
[0006] Based on the above research, the present invention provides a drug delivery system targeting Folr2-positive macrophages, comprising a drug delivery carrier and an anti-Folr2 monoclonal antibody modified on the surface of the drug delivery carrier;
[0007] The anti-Folr2 monoclonal antibody contains a heavy chain variable region and a light chain variable region. The sequence of the heavy chain variable region is shown in SEQ ID NO:1, and the sequence of the light chain variable region is shown in SEQ ID NO:2.
[0008] In one specific implementation, the drug delivery carrier is a macrophage-derived microvesicle.
[0009] This invention also provides a method for preparing a drug delivery system targeting Folr2-positive macrophages, comprising the following steps:
[0010] S1: Preparation of drug delivery carriers;
[0011] S2: Modify the surface of the drug delivery carrier with anti-Folr2 monoclonal antibody;
[0012] The anti-Folr2 monoclonal antibody contains a heavy chain variable region and a light chain variable region. The sequence of the heavy chain variable region is shown in SEQ ID NO:1, and the sequence of the light chain variable region is shown in SEQ ID NO:2.
[0013] In one specific embodiment, the drug delivery carrier is a macrophage-derived microvesicle, and S1 includes the following steps:
[0014] S11: Macrophages were cultured and collected in vitro;
[0015] S12: Starve the collected macrophages;
[0016] S13: Ultraviolet light stimulates the macrophages to produce microvesicles;
[0017] S14: Collect the microvesicles.
[0018] In one specific implementation, S2 includes the following steps:
[0019] S21: The anti-Folr2 monoclonal antibody is subjected to an amidation coupling reaction with DSPE-PEG-NHS-2000 to obtain an anti-Folr2-PEG-DSPE cross-linked complex.
[0020] S22: Mix the anti-Folr2-PEG-DSPE crosslinking complex with the microvesicles to anchor the anti-Folr2 monoclonal antibody on the surface of the microvesicles, thereby obtaining anti-Folr2-PEG-DSPE@MPs, which is the drug delivery system targeting Folr2-positive macrophages.
[0021] In one specific implementation, in S22, the mass ratio of the anti-Folr2 monoclonal antibody to the microvesicles is 2:5.
[0022] The present invention also provides a method for preparing a drug targeting Folr2-positive macrophages, comprising the step of encapsulating the cell-killing drug in the above-mentioned drug delivery system.
[0023] In one specific implementation, the cell-killing drug is doxorubicin.
[0024] The present invention also provides a drug for targeting Folr2-positive macrophages prepared by the above method.
[0025] The targeted system of this invention can precisely target Folr2-positive macrophages in kidney tissue, effectively clear pathogenic Folr2-positive macrophages in kidney tissue, inhibit renal inflammatory infiltration, reduce extracellular matrix deposition, and alleviate renal interstitial fibrosis. It is suitable for targeted therapy of acute kidney injury, chronic kidney disease, and the progression of acute kidney injury to chronic kidney disease, and has important clinical translational value and broad application prospects. Attached Figure Description
[0026] Figure 1 Construction of Folr2 monoclonal antibody. A shows electrophoresis and Coomassie brilliant blue staining of Folr2 eukaryotic expression protein; B shows electrophoresis and Coomassie brilliant blue staining of Folr1 eukaryotic expression protein; C shows the ELISA binding assay of single B cell culture supernatant with Folr1 and Folr2 proteins, screening out an antibody that binds only to Folr2 protein and not to Folr1 protein, designated 2F6; D shows the SPR surface plasmon resonance assay of antibody 2F6 with Folr2 protein, with a dissociation constant of 5.974E-8, indicating that antibody 2F6 has strong affinity and binding force to Folr2 protein.
[0027] Figure 2In vitro cell-targeted binding and internalization validation of Folr2 antibodies. In step A, the selected anti-Folr2 antibodies were incubated with Folr2-positive macrophages and negative control cells at 4°C. Immunofluorescence showed that the selected antibodies bound only to Folr2-positive macrophages. In step B, the selected anti-Folr2 antibodies were incubated with Folr2-positive macrophages and negative control cells at 37°C for 1 hour, with Fc blocking agents added simultaneously. The results showed that the anti-Folr2 antibodies could specifically internalize into Folr2-positive macrophages at 37°C, and Fc blocking did not affect Folr2-mediated internalization.
[0028] Figure 3 Folr2 antibody-modified macrophage microvesicles. A is a schematic diagram of the construction of Folr2 antibody-modified macrophage microvesicles; B shows flow cytometry analysis of Folr2 antibody-modified macrophage microvesicles generated with different antibody and microvesicle feeding ratios, showing that the binding rate reached over 75% when the antibody-to-macrophage microvesicle mass ratio was 2:5; C shows Folr2 antibody-modified macrophage microvesicles incubated with Folr2-positive macrophages and negative control cells, with immunofluorescence showing that the Folr2 antibody-modified macrophage microvesicles bound only to Folr2-positive macrophages; D shows Folr2 antibody-modified macrophage microvesicles incubated with Folr2-positive macrophages and negative control cells, with flow cytometry showing that the Folr2 antibody-modified macrophage microvesicles bound only to Folr2-positive macrophages.
[0029] Figure 4 Construction and functional validation of drug-loaded macrophage microvesicles modified with anti-Folr2 antibody. A shows a schematic diagram of the construction of drug-loaded macrophage microvesicles modified with anti-Folr2 antibody; B shows electron micrographs of Folr2 antibody-modified macrophage microvesicles and anti-Folr2 antibody-modified macrophage drug-loaded microvesicles, demonstrating successful construction; C shows immunofluorescence evidence that the anti-Folr2 antibody-modified macrophage drug-loaded microvesicles can be internalized by Folr2-positive macrophages; D shows CCK8 killing experiments performed on Folr2-positive macrophages, control negative cells, and renal tubular epithelial cells using drug-loaded macrophage microvesicles and anti-Folr2 antibody-modified macrophage drug-loaded microvesicles, respectively. The results show that the anti-Folr2 antibody-modified macrophage drug-loaded microvesicles only killed Folr2-positive macrophages, with a killing efficiency of over 50%, and did not affect the activity of negative cells and renal tubular epithelial cells.
[0030] Figure 5In vivo targeting validation of drug-loaded macrophage microvesicles modified with Folr2 antibody. A is a flowchart of in vivo imaging of drug-loaded macrophage microvesicles modified with Folr2 antibody; B is whole-body in vivo imaging of mice 24 h after tail vein injection of DIR-conjugated drug-loaded macrophage microvesicles or Folr2 antibody-modified drug-loaded macrophage microvesicles; C is in vivo imaging of an isolated kidney; D is in vivo imaging of isolated vital organs. Detailed Implementation
[0031] The principles and features of the present invention are described below. The embodiments given are only for explaining the present invention and are not intended to limit the scope of the present invention.
[0032] 1. Antigen preparation and monoclonal antibody screening
[0033] The extracellular segment of Folr2 (amino acid sites 20-221) was selected as the immunogen. This segment contains a core ligand binding pocket and a dominant antigenic epitope. At the same time, the Folr1 eukaryotic protein was constructed for reverse screening to exclude cross-reaction with proteins of the same family, and finally a highly specific and high-affinity anti-Folr2 monoclonal antibody was obtained.
[0034] Recombinant mouse Folr2 extracellular protein antigen was synthesized using a solid-phase synthesis method, and sequencing verified that the polypeptide sequence was completely correct. SDS-PAGE electrophoresis showed that the target protein was expressed in the soluble supernatant. Figure 1 A), protein concentration 0.67 mg / mL, purity >90%, no degradation during expression. Simultaneously, the Folr1 eukaryotic control protein was synthesized using the same method, with a protein concentration of 1.386 mg / mL, and purity meeting experimental requirements (…). Figure 1 (B) can be used for antibody-specific reverse screening.
[0035] Healthy female New Zealand white rabbits aged 4 months and weighing 2.1 kg were selected as immunization animals. The initial immunization used Freund's complete adjuvant mixed with an equal volume of Folr2 protein antigen in an emulsion. Subsequent booster immunizations used Freund's incomplete adjuvant mixed with the antigen emulsion system. Multiple immunizations were completed strictly according to the established cycle. The specific immunization protocol is as follows:
[0036] First vaccination (November 25, 2022): Freund's complete adjuvant + 1.6 mg Folr2 protein antigen;
[0037] Second immunization (December 9, 2022): Freund's incomplete adjuvant + 0.8 mg Folr2 protein antigen;
[0038] Three-fold exemption (December 23, 2022): Freund's incomplete adjuvant + 0.8 mg Folr2 protein antigen;
[0039] Four-fold exemption (January 6, 2023): Freund's incomplete adjuvant + 0.8 mg Folr2 protein antigen;
[0040] Post-immunization test (January 13, 2023): 1 mL of rabbit peripheral blood was collected, and antiserum was separated for ELISA titer detection;
[0041] Five-fold exemption (February 23, 2023): Freund's incomplete adjuvant + 0.8 mg Folr2 protein antigen;
[0042] Final sampling (March 2, 2023): Whole blood was collected from the carotid artery, incubated overnight at 4°C, serum was separated and frozen, spleen cells were aseptically separated and frozen in liquid nitrogen for later use.
[0043] Antibody titers were detected using an indirect ELISA method.
[0044] Peripheral blood B cells were collected from immunized rabbits. The cells were washed twice with 50 mL of washing buffer, centrifuged at 1500 rpm for 5 min, and the supernatant was discarded to collect the cell pellet. B cells were targeted for selection using the Folr2 specific antigen to obtain positive specific B cells. After counting the positive B cells, limiting dilutions were performed, and the cells were seeded into 96-well plates for monoclonal culture. After 15 days of incubation at a constant temperature, the cell supernatant was collected for ELISA detection to screen for highly positive monoclonal cell lines. Results are as follows: Figure 1 As shown in C, an antibody that binds only to Folr2 protein and not to Folr1 protein was screened out and was numbered 2F6. Its heavy chain variable region sequence is shown in SEQ ID NO:1 and its light chain variable region sequence is shown in SEQ ID NO:2.
[0045] ELISA testing confirmed that the purified recombinant antibody achieved an OD value of 0.909 at a dilution of 256K, with an estimated antibody titer >512K, demonstrating excellent affinity and specificity.
[0046] 2. Antibody Recombinant Expression and Purification
[0047] Recombinant antibody expression was performed using the HEK293 mammalian cell expression system. Cells were seeded at a density of 1.5–2.0 × 10⁶ cells / mL, cultured at 37°C, and shaken at 130 rpm / min for 6 days. The supernatant was collected after 6 days of continuous culture. The collected cell culture supernatant was centrifuged at high speed and filtered through a 0.22 μm filter. Antibody purification was performed using Protein A resin. The equilibration and washing buffers were pH 7.4 PBS, and the elution buffer was pH 3.0 0.1 M glycine solution. After elution, the antibody was neutralized with pH 8.5 1 M Tris-Cl solution to obtain the purified recombinant Folr2 monoclonal antibody.
[0048] The recombinant Folr2 monoclonal antibody was detected using surface plasmon resonance (SPR) and immunofluorescence assays. The results are as follows: Figure 1 As shown in D and Table 1, this antibody can specifically bind to the Folr2 antigen, has no cross-reactivity with Folr1, and possesses high affinity and high specificity. It can stably recognize Folr2-positive macrophages and mediate internalization under the action of Folr2, thus meeting the requirements for targeted modification applications.
[0049] Table 1. Affinity constant analysis of recombinant monoclonal antibodies
[0050]
[0051] The selected anti-Folr2 antibodies were incubated with Folr2-positive macrophages and negative control cells at 4°C. Immunofluorescence showed that the selected antibodies bound only to Folr2-positive macrophages. Figure 2 A).
[0052] The selected anti-Folr2 antibodies were incubated with Folr2-positive macrophages and negative control cells at 37°C for 1 hour, respectively, while Fc blocking agents were added to each group. The results showed that the anti-Folr2 antibodies could specifically internalize into Folr2-positive macrophages at 37°C, and Fc blocking did not affect Folr2-mediated internalization. Figure 2 B).
[0053] 3. Preparation and extraction of macrophage microvesicles
[0054] RAW264.7 macrophages were cultured in vitro using DMEM complete medium and a conventional culture system. Once the cell confluence density reached over 90%, microvesicles were extracted and prepared. The specific steps are as follows:
[0055] Discard the original supernatant culture medium from the culture dishes, add 2 mL of PBS buffer to wash the cells, and remove residual serum culture medium; add 15 mL of serum-free DMEM culture medium to each dish and starve the cells for 24 h; then irradiate the cells with 38 W UV light for 1 h and incubate overnight at 37℃. The next day, collect all cell suspensions, centrifuge horizontally at 4000 rpm for 10 min to remove cell and tissue debris; collect the supernatant, centrifuge at 14000 rpm for 30 min, and the precipitate is macrophage microvesicles. Resuspend the precipitate in sterile 1×PBS, determine the microvesicle protein concentration using the BCA method, aliquot and store at -80℃ for later use.
[0056] 4. Construction of a Folr2 antibody-modified macrophage microvesicle drug delivery system
[0057] The DSPE-PEG-NHS crosslinking system was used to achieve stable conjugation of Folr2 antibody to macrophage microvesicles, such as... Figure 3 As shown in A, the specific preparation steps are as follows:
[0058] 1) Preparation of fluorescently labeled Folr2 antibody cross-linked complex
[0059] Anti-Folr2 antibody was fluorescently labeled with CY3. 20 molar amounts of DSPE-PEG-NHS-2000 (dissolved in DMSO) were added to the antibody solution, and the mixture was continuously stirred in a rotary mixer for 24 hours to complete the amidation coupling reaction between the antibody and the phospholipid linker. After the reaction, the mixture was centrifuged at 14000g and 4℃ for 10 min using a 30kDa ultrafiltration tube to remove unreacted free DSPE-PEG-NHS. The concentrated product was then resuspended in sterile 1×PBS to obtain the CY3@anti-Folr2-PEG-DSPE crosslinked complex.
[0060] 2) Fluorescent labeling of macrophage microvesicles
[0061] Macrophage microvesicles were labeled with DID fluorescent dye and stirred continuously at room temperature in the dark for 45 min. After labeling, the microvesicles were centrifuged at 14,000 rpm and 4 °C for 30 min to remove free DID dye. The precipitate was resuspended in sterile 1×PBS to obtain DID-labeled macrophage microvesicles (DID@MPs).
[0062] 3) Antibody-modified microvesicle assembly
[0063] The FITC-labeled anti-Folr2-PEG-DSPE complex and DID@MPs were mixed at the optimal mass modification ratio and stirred at 37°C for 2 hours on a shaker. Utilizing the hydrophobic end of DSPE intercalating into the phospholipid bilayer of microvesicles, stable antibody anchoring was achieved, while the PEG chain enhanced the biocompatibility and stability of the system. After the reaction, the mixture was centrifuged at 14,000 rpm for 30 min to remove unbound free antibody complexes. The mixture was then resuspended and concentrated in sterile 1×PBS to obtain the FITC@anti-Folr2-PEG-DSPE@MPs targeted drug delivery system. Flow cytometry was used to detect FITC and DID double-positive signals to verify the antibody modification success rate and microvesicle integrity.
[0064] The results are as follows Figure 3 As shown, flow cytometry analysis of macrophage microvesicles modified with Folr2 antibodies generated at different antibody-to-microvesicle ratios showed that the binding rate reached over 75% when the antibody-to-macrophage microvesicle mass ratio was 2:5. Figure 3B). Folr2 antibody-modified macrophage microvesicles were incubated with Folr2-positive macrophages and negative control cells, respectively. Immunofluorescence showed that Folr2 antibody-modified macrophage microvesicles only bound to Folr2-positive macrophages (B). Figure 3 C). Folr2 antibody-modified macrophage microvesicles were incubated with Folr2-positive macrophages and negative control cells, respectively. Flow cytometry showed that Folr2 antibody-modified macrophage microvesicles only bound to Folr2-positive macrophages (C). Figure 3 D)
[0065] 5. Antibody-modified macrophage drug-loaded microvesicles
[0066] The process of constructing antibody-modified macrophage drug-loaded microvesicles is as follows: Figure 4 As shown in Figure A.
[0067] RAW macrophages in the logarithmic growth phase were selected, replaced with fresh complete culture medium, and placed on a UV irradiation bench for 1 h. UV stress stimulated macrophage activation and enhanced microvesicle secretion. After UV treatment, doxorubicin (DOX) solution was added to the cell culture medium, mixed well, and incubated at 37℃ in a 5% CO2 incubator for 24 h in the dark to allow DOX to fully enter the macrophage cells for drug loading. After incubation, the macrophage culture supernatant was collected, and microvesicles were separated and purified using a gradient centrifugation method. Suspended cells and cell debris were removed by sequential centrifugation at 300×g for 10 min and 2000×g for 20 min. The supernatant was then ultracentrifuged at 120000×g for 90 minutes. The precipitate was collected, resuspended in sterile PBS, and repeatedly centrifuged and washed twice to remove residual free DOX and impurities, yielding a purified macrophage DOX-loaded microvesicle suspension. The purified drug-loaded microvesicles were then mixed with an anti-Folr2-PEG-DSPE crosslinking complex and incubated with gentle shaking at room temperature for 2 h. The anti-Folr2 antibody was stably anchored to the microvesicle surface via the PEG-DSPE membrane intercalation properties. After incubation, unbound free components were removed by centrifugation and washing with sterile PBS, resulting in anti-Folr2 modified macrophage DOX-loaded microvesicles. Electron micrographs of Folr2 antibody-modified macrophage microvesicles and anti-Folr2 antibody-modified drug-loaded macrophage microvesicles are shown below. Figure 4 As shown in Figure B, the antibody-modified drug-loaded macrophage microvesicles were successfully constructed.
[0068] Four-week-old male C57BL / 6 mice were selected, and bone marrow mononuclear cells were aseptically extracted. They were cultured in DMEM complete medium containing 20% L929 cell supernatant, 10% fetal bovine serum, and 1% penicillin-dextrose antibody for 7 days to obtain mature bone marrow-derived macrophages (BMDM). BMDM were induced with 100 ng / mL IL-34 cytokine to construct a Folr2-positive macrophage model.
[0069] Fitc@anti-Folr2-PEG-DSPE@MPs were added to the cell culture system and incubated at 37°C for 4 h. After incubation, flow cytometry and immunofluorescence were used to detect the uptake efficiency of microvesicles by Folr2-positive macrophages in each group, to verify the targeting recognition ability and specificity of anti-Folr2 modified microvesicles.
[0070] The results are as follows Figure 4 As shown, immunofluorescence revealed that drug-loaded microvesicles modified with anti-Folr2 antibody could be internalized by Folr2-positive macrophages. Figure 4 C). CCK8 killing assays were performed on Folr2-positive macrophages, control negative cells, and renal tubular epithelial cells using drug-loaded macrophage microvesicles modified with anti-Folr2 antibody, respectively. The results showed that the drug-loaded macrophage microvesicles modified with anti-Folr2 antibody only killed Folr2-positive macrophages, with a killing efficiency exceeding 50%, and did not affect the activity of negative cells and renal tubular epithelial cells. Figure 4 D).
[0071] The above experimental results confirm that the drug delivery system prepared in this invention can efficiently and specifically target Folr2-positive macrophages, with significantly better targeting performance than unmodified natural microvesicles. The targeting uptake efficiency decreases significantly after receptor blockade, confirming that its targeting effect depends on the specific binding of Folr2 antigen-antibody.
[0072] 6. In vivo targeting validation of the targeted drug delivery system
[0073] The in vivo imaging workflow for Folr2 antibody-modified macrophage drug-loaded microvesicles is as follows: Figure 5 As shown in Figure A.
[0074] Take the above-modified targeted drug-loaded microvesicle suspension, add an appropriate final concentration of DIR cell membrane fluorescent probe, and incubate at 37°C in the dark for 15 min to allow DIR to be uniformly embedded in the microvesicle cell membrane structure. After labeling, wash repeatedly with sterile PBS to remove unbound free DIR probes, and finally prepare DIR-conjugated anti-Folr2 modified macrophage DOX-loaded microvesicles. Store at 4°C in the dark for a short period of time for later use.
[0075] A mouse model of renal ischemia-reperfusion (I / R) injury was established using the left renal pedicle clamping method. The left renal pedicle was completely clamped with a non-invasive microsurgical hemostatic clip to block renal blood flow. During clamping, the color change of the kidney was observed; a change from bright red to dark red and congested indicated successful ischemia. After 35 minutes of ischemia, the hemostatic clip was slowly released to restore blood flow to the left kidney. The rapid return of the kidney color from dark red to a healthy red indicated successful reperfusion. The abdominal wall muscles and skin were sutured layer by layer. Postoperatively, the wound was disinfected with povidone-iodine. The mice were placed on a warming mat for resuscitation and were fed and watered freely according to standard care.
[0076] Mice were routinely fed until day 5 post-surgery, then administered targeted microvesicle drug via tail vein. DIR-labeled anti-Folr2 modified macrophage DOX-loaded microvesicles were diluted with sterile saline to a pre-determined concentration and administered via a single tail vein injection. The injection volume was standardized based on mouse body weight. A blank control group (injected with an equal volume of sterile saline) and a control group without Folr2 modification, consisting of DIR-labeled macrophage DOX-loaded microvesicles (non-targeted microvesicle group), were also established. Sufficient biological replicates were performed for each group to ensure the reliability of the experimental results. Mice were fed normally after drug administration, with fasting but free access to water.
[0077] Before the test, mice were anesthetized with isoflurane inhalation, fixed on the in vivo imaging system platform, and kept in a prone position to fully expose the corresponding area of the kidneys in the abdomen. The position was adjusted to a uniform standard to eliminate the influence of positional differences on the imaging results. A DIR-specific fluorescence detection channel was set up, and whole-body fluorescence imaging scans were performed on mice in each group. The fluorescence signal intensity and distribution range of the left ischemia-reperfusion injured kidney, the right normal kidney, and major organs such as the heart, liver, spleen, and lungs were observed. After imaging, the mice were euthanized, and both kidneys and major organs were dissected and separated for in vitro tissue fluorescence imaging. This further verified the specificity of targeted microvesicle enrichment in damaged kidney tissue, compared the fluorescence signal differences between normal and damaged kidney tissue, and quantitatively analyzed the tissue fluorescence grayscale values of each group.
[0078] Whole-body in vivo imaging images of mice 24 hours after tail vein injection of DIR-conjugated drug-loaded macrophage microvesicles or Folr2 antibody-modified drug-loaded macrophage microvesicles. Figure 5 As shown in Figure B, in vivo imaging of the isolated kidney is as follows: Figure 5 As shown in C, in vivo imaging of vital organs outside the body is as follows: Figure 5 As shown in D, the results all showed that the fluorescence intensity of the damaged kidney in the left side of the mice in the anti-Folr2 modified macrophage DOX microvesicle group was significantly higher than that in the right side of the healthy kidney, while there was no significant difference in fluorescence intensity between the two kidneys in the non-targeted microvesicle group, indicating that the present invention can specifically target the damaged kidney.
[0079] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A drug delivery system targeting Folr2-positive macrophages, characterized in that, Includes a drug delivery carrier and an anti-Folr2 monoclonal antibody modified on the surface of the drug delivery carrier; The anti-Folr2 monoclonal antibody contains a heavy chain variable region and a light chain variable region. The sequence of the heavy chain variable region is shown in SEQ ID NO:1, and the sequence of the light chain variable region is shown in SEQ ID NO:
2.
2. The drug delivery system according to claim 1, characterized in that, The drug delivery carrier is a macrophage-derived microvesicle.
3. A method for preparing a drug delivery system targeting Folr2-positive macrophages, characterized in that, Includes the following steps: S1: Preparation of drug delivery carriers; S2: Modify the surface of the drug delivery carrier with anti-Folr2 monoclonal antibody; The anti-Folr2 monoclonal antibody contains a heavy chain variable region and a light chain variable region. The sequence of the heavy chain variable region is shown in SEQ ID NO:1, and the sequence of the light chain variable region is shown in SEQ ID NO:
2.
4. The preparation method according to claim 3, characterized in that, The drug delivery carrier is a macrophage-derived microvesicle, and S1 includes the following steps: S11: Macrophages were cultured and collected in vitro; S12: Starve the collected macrophages; S13: Ultraviolet light stimulates the macrophages to produce microvesicles; S14: Collect the microvesicles.
5. The preparation method according to claim 4, characterized in that, S2 includes the following steps: S21: The anti-Folr2 monoclonal antibody is subjected to an amidation coupling reaction with DSPE-PEG-NHS-2000 to obtain an anti-Folr2-PEG-DSPE cross-linked complex. S22: Mix the anti-Folr2-PEG-DSPE crosslinking complex with the microvesicles to anchor the anti-Folr2 monoclonal antibody on the surface of the microvesicles, thereby obtaining anti-Folr2-PEG-DSPE@MPs, which is the drug delivery system targeting Folr2-positive cells.
6. The preparation method according to claim 5, characterized in that, In S22, the mass ratio of the anti-Folr2 monoclonal antibody to the microvesicles is 2:
5.
7. A method for preparing a drug targeting Folr2-positive macrophages, characterized in that, The step includes encapsulating a cell-killing drug using the drug delivery system described in claim 1 or 2.
8. The method according to claim 7, characterized in that, The cell-killing drug is doxorubicin.
9. A drug targeting Folr2-positive macrophages, characterized in that, It is prepared by the method described in claim 7 or 8.
